Clinical trials: Breast Cancer in Situ
Breast Cancer, Dermatologic Complications
Mometasone Furoate in Preventing Radiation Dermatitis in Patients Undergoing Radiation Therapy to the Breast or Chest Wall for Invasive Breast Cancer or Ductal Carcinoma in Situ
RATIONALE: Steroid therapy, such as mometasone furoate, may prevent radiation dermatitis caused by radiation therapy. It is not yet known whether mometasone furoate is more effective than a placebo in preventing radiation…
- Conditions
- Breast Cancer, Dermatologic Complications, Radiation Toxicity, Skin Reactions Secondary to Radiation Therapy
- Trial name
- NCT00438659
- Testing
- mometasone furoate
- Where
- 189 sites in United States
- Volunteers
- 176 people
- Sponsor
- North Central Cancer Treatment Group
Breast Cancer
Effect of Tamoxifen or an Aromatase Inhibitor on Estrogen Metabolism in Women Treated for Newly Diagnosed Breast Cancer
RATIONALE: Studying samples of urine in the laboratory from women with breast cancer may help doctors learn whether tamoxifen and aromatase inhibitors alter the metabolism of estrogens.
- Trial name
- NCT00569543
- Testing
- high performance liquid chromatography, laboratory biomarker analysis, mass spectrometry
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- University of Nebraska
Breast Carcinoma, Pain
Prophylactic Topical Agents in Reducing Radiation-Induced Dermatitis in Patients With Non-inflammatory Breast Cancer
This randomized pilot phase II trial studies and compares prophylactic topical agents in reducing radiation-induced dermatitis in patients with non-inflammatory breast cancer or breast cancer in situ.
- Conditions
- Breast Carcinoma, Pain, Radiation-Induced Dermatitis, Stage 0 Breast Cancer
- Trial name
- Curcumin-II (NCT02556632)
- Testing
- Curcumin-based Gel, Dermatologic Complications Management, Laboratory Biomarker Analysis
- Where
- 6 sites in United States
- Volunteers
- 191 people
- Sponsor
- Gary Morrow
DCIS
The AUS-PREDICT Registry for DCIS Patients With DCISionRT Testing
This is a prospective cohort study for patients diagnosed with ductal carcinoma in situ (DCIS) of the breast. The primary objective of the study is to create a de-identified database of patients, test results, treatment decisions…
- Trial name
- AUS-PREDICT (NCT04916808)
- Testing
- DCISionRT Test
- Where
- 2 sites in Australia
- Volunteers
- 1,500 people
- Sponsor
- PreludeDx
Breast Cancer in Situ
Breast Screening & Patient Navigation (BSPAN2): Evaluating a De-Centralized Regional Delivery System for Rural Underserved
The investigators will expand BSPan's reach and sustainability by systematizing how to enable counties to assume responsibility for one or two of the components while Moncrief/uTSW continues to provide centralized financial…
- Trial name
- NCT03052907
- Testing
- BSPAN
- Volunteers
- 18,540 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8
Culturally Based Brief Expressive Writing Intervention for the Improvement of Health in Chinese Immigrant Stage 0-III Breast Cancer Survivors, Writing to Heal Study
This clinical trial studies the effect of a culturally based brief expressive writing intervention in improving the health of Chinese immigrant stage 0-III breast cancer survivors.
- Conditions
- Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8
- Trial name
- NCT04754412
- Testing
- Behavioral, Psychological or Informational Intervention, Best Practice, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 256 people
- Sponsor
- M.D. Anderson Cancer Center
Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation
Diabetes Prevention Program With or Without Hunger Training in Helping to Lower Breast Cancer Risk in Obese Participants
This pilot trial studies how well a diabetes prevention program with or without hunger training works in helping to lower breast cancer risk in obese participants.
- Conditions
- Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Ductal Breast Carcinoma In Situ, Obesity
- Trial name
- NCT03546972
- Testing
- Behavioral, Psychological or Informational Intervention, Questionnaire Administration
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer, DCIS
LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast Cancer
The aim of this Phase 1b/2 study is to investigate the safety, efficacy, and pharmacokinetics (PK) of a single dose of LS301-IT, a novel fluorescence imaging agent developed by Integro Theranostics (IT), administered by…
- Conditions
- Breast Cancer, DCIS, Invasive Duct Carcinoma of Breast
- Trial name
- NCT05900986
- Testing
- LS301-IT 0.025 mg/kg, LS301-IT 0.05 mg/kg, LS301-IT 0.075 mg/kg
- Where
- 9 sites in United States
- Volunteers
- 22 people
- Sponsor
- Integro Theranostics
Ductal Breast Carcinoma In Situ
MRI and Gene Expression in Diagnosing Patients With Ductal Breast Cancer In Situ
This clinical trial studies magnetic resonance imaging (MRI) and gene expression in diagnosing patients with abnormal cells in the breast duct that have not spread outside the duct.
- Trial name
- NCT02352883
- Testing
- Magnetic Resonance Imaging, Therapeutic Conventional Surgery, Therapeutic Surgical Procedure
- Where
- 76 sites in United States
- Volunteers
- 368 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Breast Cancer
Combination Chemotherapy With or Without Trastuzumab Followed By an Autologous Stem Cell Transplant and Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00182793
- Testing
- trastuzumab, carboplatin, cyclophosphamide
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- City of Hope Medical Center
Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia
Adding a Genetic Risk Evaluation to Standard Breast Cancer Risk Assessment for African American and Hispanic Women
This study evaluates whether adding a polygenic risk score evaluation to standard breast cancer risk assessment tools helps African American and Hispanic women make more informed decisions about accepting additional breast cancer…
- Conditions
- Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia, Breast Carcinoma, Breast Lobular Carcinoma In Situ
- Trial name
- NCT05755269
- Testing
- Biospecimen Collection, Genotyping, Survey Administration
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Mayo Clinic
Breast Cancer
BrUOG 291: Five Fraction Partial Breast Irradiation Using Non-invasive Image-guided Breast Brachytherapy (NIBB)
To evaluate safety of 5 fraction accelerated partial brest irradiation in more convenient 5 fraction schedule.
- Trial name
- NCT01961531
- Testing
- Accuboost APBI
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Brown University
Breast Cancer
Radiation Therapy After Lumpectomy in Treating Women With Ductal Carcinoma in Situ or Invasive Breast Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Giving radiation during surgery followed by external-beam radiation to the entire breast may kill more tumor cells.
- Trial name
- NCT00054301
- Testing
- adjuvant therapy, conventional surgery, intraoperative radiation therapy
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Case Comprehensive Cancer Center
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8
Hypnosedation in Relaxing Patients Undergoing Breast Cancer Surgery
This clinical trial studies how well hypnosedation works in relaxing and reducing the need for general anesthesia in patients who are undergoing breast cancer surgery.
- Conditions
- Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8
- Trial name
- NCT03012399
- Testing
- Hypnosedation, Questionnaire Administration, Verbal Support
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
Study of Biomarkers in Blood and/or Tumor Tissue Samples From Patients With Ductal Carcinoma in Situ and From Healthy Volunteers
RATIONALE: Studying genes in samples of blood and/or tumor tissue from patients with cancer may help doctors identify biomarkers related to cancer.
- Trial name
- NCT00935233
- Testing
- DNA analysis, polymorphism analysis, protein analysis
- Where
- 18 sites in United Kingdom
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Queen Mary University of London
Breast Cancer
Evaluating the Safety and Efficacy of a Novel Accelerated Partial Breast Irradiation Regimen
This study will use an adjuvant radiation therapy regimen called APBI (accelerated partial breast irradiation). APBI is a treatment option available to women considered to have an early stage, low-risk breast cancer.
- Trial name
- APBI RISE (NCT05591547)
- Testing
- IMRT/VMAT-Based Accelerated Partial Breast Irradiation
- Where
- 2 sites in United States
- Volunteers
- 91 people
- Sponsor
- Sanford Health
Breast Cancer
Radiation Therapy in Treating Women With Locally Recurrent Breast Cancer Previously Treated With Repeat Breast-Preserving Surgery
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation therapy after surgery kill any remaining tumor cells and may be an effective treatment for breast cancer.
- Trial name
- NCT01082211
- Testing
- 3D-Conformal External Beam
- Where
- 58 sites in United States, Canada
- Volunteers
- 65 people
- Sponsor
- Radiation Therapy Oncology Group
Neoplasms, Breast
Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer
This study is being conducted to compare the efficacy and safety of pazopanib in combination with lapatinib with that of lapatinib alone in subjects with locally advanced or metastatic breast cancer whose tumors overexpress the…
- Trial name
- NCT00347919
- Testing
- pazopanib (GW786034) 400 mg, lapatinib (GW572016) 1500 mg, lapatinib (GW572016) 1000 mg
- Where
- 84 sites in United States, Canada and 14 more
- Volunteers
- 189 people
- Sponsor
- GlaxoSmithKline
Ductal Carcinoma in Situ, Lobular Carcinoma in Situ
CAN1012 in Pre-Malignant DCIS and LCIS
This is a Phase I/Ib study evaluating CAN1012 in patients with ductal carcinoma in situ and lobular carcinoma in situ.
- Trial name
- NCT07408856
- Testing
- CAN1012
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Providence Health & Services
Breast Cancer
Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using either tamoxifen or anastrozole may fight breast cancer by blocking the use of estrogen.
- Trial name
- IBIS-II DCIS (NCT00072462)
- Testing
- tamoxifen citrate, Anastrozole
- Where
- 97 sites in Australia, Austria and 12 more
- Volunteers
- 2,980 people
- Sponsor
- Queen Mary University of London